Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes (EA3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02874638
Recruitment Status : Completed
First Posted : August 22, 2016
Last Update Posted : April 1, 2019
Sponsor:
Collaborator:
Ajinomoto Co., Inc.
Information provided by (Responsible Party):
Daniel Moore, University of Toronto

Brief Summary:

Protein requirements in individuals who participate in endurance-based exercise training have been suggested to be greater than the current recommended dietary allowance (RDA).

The biological value of protein depends on its amino acid composition. Essential amino acids are believed to have main role on whole body protein metabolism. However, it remains to be determined what role non-essential amino acids (NEAA) may have in regulating protein metabolism and contributing to the increased protein requirements after endurance exercise.

The indicator amino acid oxidation (IAAO) method has clarified the individual amino acid requirement in children, normal healthy adult and clinical populations. However, the IAAO method has never been utilized for assessing the effect of NEAA on protein requirements after endurance exercise.

The objective of the current study is to investigate the importance of NEAA for endurance-trained male subjects.


Condition or disease Intervention/treatment Phase
Increased Metabolic Requirement Healthy Dietary Supplement: BASE egg protein Dietary Supplement: BCAA-enriched egg protein Dietary Supplement: small amount of essential amino acids Dietary Supplement: large amount of essential amino acids Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes Using Indicator Amino Acid Oxidation Method.
Actual Study Start Date : September 2016
Actual Primary Completion Date : August 2017
Actual Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BASE egg protein
0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
Dietary Supplement: BASE egg protein
0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein

Experimental: BCAA-enriched egg protein
branched-chain amino acid-enriched egg protein
Dietary Supplement: BCAA-enriched egg protein
BCAA-enriched egg protein provided as crystalline amino acid.

Experimental: small amount of essential amino acids
small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
Dietary Supplement: small amount of essential amino acids
essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein

Experimental: large amount of essential amino acids
large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
Dietary Supplement: large amount of essential amino acids
essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein




Primary Outcome Measures :
  1. 13CO2 (carbon dioxide) excretion rate (μmol/kg/h) [ Time Frame: at 8 hours after the end of exercise] ]
    8 hours after exercise followed by ingesting 13C-labelled phenylalanine and one of 5 different amount of amino acids intake, 13CO2 excretion rate is determined by multiplying the enrichment of 13CO2 in breath measured by Mass spectrometry and CO2 production rate measured by metabolic cart.


Secondary Outcome Measures :
  1. [13C]phenylalanine oxidation rate (μmol/kg/h) [ Time Frame: at 8 hours after the end of exercise ]
    8 hours after exercise followed by ingesting 13C-labelled phenylalanine and one of 5 different amount of amino acids intake, 13CO2 excretion rate is determined dividing 13CO2 excretion rate by urinary enrichment of 13C-phenylalanine in breath measured by Mass spectrometry, and CO2 production rate measured by metabolic cart.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • endurance-trained participants who regularly run more than 40 km/week
  • Participants who are categorized at least "very good" based on a study by Shvartz & Reibold, in which VO2peak is used as an index. (i.e. the participants whose VO2peak is ≥57 ml/kg/min (18-24 y), ≥54 ml/kg/min (25-29 y), ≥52 ml/kg/min (30-34 y), ≥49 ml/kg/min (35-39 y)
  • Ability to complete the 16-km familiarization run in session 2

Exclusion Criteria:

  • Inability to meet health and physical activity guidelines according to the physical activity readiness questionnaire (PAR-Q+)
  • Inability to adhere to any of the protocol guidelines (i.e. alcohol, caffeine consumption)
  • Regular tobacco use
  • Illicit drug use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02874638


Sponsors and Collaborators
University of Toronto
Ajinomoto Co., Inc.
Investigators
Layout table for investigator information
Principal Investigator: Daniel Moore, Ph.D. University of Toronto

Layout table for additonal information
Responsible Party: Daniel Moore, Assistant Professor, University of Toronto
ClinicalTrials.gov Identifier: NCT02874638     History of Changes
Other Study ID Numbers: IAAO-EA3
First Posted: August 22, 2016    Key Record Dates
Last Update Posted: April 1, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No